Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRK-439 · 1 trial · 1 indication
• Incidence of AEs
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Participants will be treated with a single dose of SRK-439 or matching placebo. |
| Part B | EXPERIMENTAL | Participants will be treated with multiple doses of SRK-439 or matching placebo. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo to SRK-439, subcutaneous administration |
| SRK-439 | DRUG | Single ascending dose, subcutaneous administration |
Key Inclusion Criteria: 1. Male or female participants, ≥18 to ≤55 years of age, at the time of informed consent 2. BMI of ≥18 kg/m2 to ≤35 kg/m2 (inclusive) at screening Exclusion Criteria: 1. Previous treatment with SRK-439 or apitegromab, or with other anti-myostatin therapies, including ACTR ...
SRK-439 is an investigational small molecule being developed by Scholar Rock Holding Corporation (ticker: SRRK). It is currently in Phase 1 clinical development for healthy adults. The drug targets myostatin, a protein involved in muscle regulation, and is being studied in a single- and multiple-ascending dose trial.
SRK-439 targets myostatin, a protein that regulates muscle growth. By targeting myostatin, the drug is designed to potentially modulate muscle-related pathways. This mechanism is being evaluated in a Phase 1 study in healthy adults to assess safety and tolerability.
SRK-439 is being developed by Scholar Rock Holding Corporation, a biopharmaceutical company traded under the ticker SRRK. The company is conducting a Phase 1 clinical trial of SRK-439 in healthy adults in the United States.
SRK-439 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 study is a single- and multiple-ascending dose trial in healthy adults, currently recruiting participants.
SRK-439 is being studied in one Phase 1 clinical trial, identified as NCT07444294. This is a randomized, double-blind, controlled study titled 'A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults.' The trial is recruiting 76 healthy participants aged 18 years and older in the United States.
SRK-439 is not known to have alternative names. It is a distinct investigational small molecule developed by Scholar Rock. No other names for this drug have been reported in the available clinical trial information.